Abstract
Introduction Individuals with COVID-19 frequently experience symptoms and impaired quality of life beyond 4-12 weeks, commonly referred to as Long COVID. Whether Long COVID is one or several distinct syndromes is unknown. Establishing the evidence base for appropriate therapies is needed. We aim to evaluate the symptom burden and underlying pathophysiology of Long COVID syndromes in non-hospitalised individuals and evaluate potential therapies.
Methods and analysis A cohort of 4000 non-hospitalised individuals with a past COVID-19 diagnosis and 1000 matched controls will be selected from anonymised primary care records from the Clinical Practice Research Datalink (CPRD) and invited by their general practitioners to participate on a digital platform (Atom5™). Individuals will report symptoms, quality of life, work capability, and patient reported outcome measures. Data will be collected monthly for one year.
Statistical clustering methods will be used to identify distinct Long COVID symptom clusters. Individuals from the four most prevalent clusters and two control groups will be invited to participate in the BioWear sub-study which will further phenotype Long COVID symptom clusters by measurement of immunological parameters and actigraphy.
We will review existing evidence on interventions for post-viral syndromes and Long COVID to map and prioritise interventions for each newly characterised Long COVID syndrome. Recommendations will be made using the cumulated evidence in an expert consensus workshop. A virtual supportive intervention will be coproduced with patients and health service providers for future evaluation.
Individuals with lived experience of Long COVID will be involved throughout this programme through a patient and public involvement group.
Ethics and dissemination Ethical approval was obtained from the Solihull Research Ethics Committee, West Midlands (21/WM/0203). The study is registered on the ISRCTN Registry (1567490). Research findings will be presented at international conferences, in peer-reviewed journals, to Long COVID patient support groups and to policymakers.
Strengths and limitations of the study
The study will generate a nationally representative cohort of individuals with Long COVID recruited from primary care.
We will recruit controls matched on a wide range of demographic and clinical factors to assess differences in symptoms between people with Long COVID and similar individuals without a history of COVID-19.
We will use a newly developed electronic patient reported outcome measure (Symptom Burden Questionnaire™) for Long COVID to comprehensively assess a wide range of symptoms highlighted by existing literature, patients, and clinicians.
Immunological, proteomic, genetic, and wearable data captured in the study will allow deep phenotyping of Long COVID syndromes to help better target therapies.
A limitation is that a significant proportion of non-hospitalised individuals affected by COVID-19 in the first wave of the pandemic will lack confirmatory testing and will be excluded from recruitment to the study.
Competing Interest Statement
MC is Director of the Birmingham Health Partners Centre for Regulatory Science and Innovation, Director of the Centre for the Centre for Patient Reported Outcomes Research and is a National Institute for Health Research (NIHR) Senior Investigator. MC receives funding from the National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, the NIHR Surgical Reconstruction and Microbiology Research Centre and NIHR ARC West Midlands at the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Health Data Research UK, Innovate UK (part of UK Research and Innovation), Macmillan Cancer Support, UCB Pharma, Janssen, GSK and Gilead. MC has received personal fees from Astellas, Aparito Ltd, CIS Oncology, Takeda, Merck, Daiichi Sankyo, Glaukos, GSK and the Patient-Centered Outcomes Research Institute (PCORI) outside the submitted work. SEH is supported by the National Institute for Health Research (NIHR) Applied Research Centre (ARC), West Midlands at the University of Birmingham. SEH has received personal fees from Cochlear Ltd and Aparito Ltd outside the submitted work. OLA receives funding from the NIHR Birmingham Biomedical Research Centre (BRC), NIHR Applied Research Centre (ARC), West Midlands at the University of Birmingham and University Hospitals Birmingham NHS Foundation, Innovate UK (part of UK Research and Innovation), Gilead Sciences Ltd, and Janssen pharmaceuticals, Inc. OLA declares personal fees from Gilead Sciences Ltd, GlaxoSmithKline (GSK) and Merck outside the submitted work. CM receives funding from the National Institute for Health Research (NIHR) Surgical Reconstruction and Microbiology Research Centre, Innovate UK, and has received personal fees from Aparito Ltd outside the submitted work. PM, TW, CI and EL are employees of CPRD, the data custodians for CPRD Aurum. CPRD is jointly sponsored by the UK government Medicines and Healthcare products Regulatory Agency and the National Institute for Health Research (NIHR). As a not-for-profit UK government body, CPRD seeks to recoup the cost of delivering its research services to academic, industry and government researchers through research user license fees. JC is a lay member on the UK NICE COVID expert panel, a citizen partner to the COVID END Evidence Synthesis Network, PPI lead on the NIHR CICADA ME Study, patient representative at the EAN European Neurology Autonomic Nervous Systems Disorders Working Group, a member of the MRC/UKRI Advanced Pain Discovery Platform, and external board member of Plymouth Institute of Health. She also reports contracts with GSK and Medable. All other co-authors have no relevant competing interests to declare.
Funding Statement
This work is independent research jointly funded by the National Institute for Health Research (NIHR) and UK Research and Innovation (UKRI) (Therapies for Long COVID in non-hospitalised individuals: From symptoms, patient reported outcomes and immunology to targeted therapies (The TLC Study), COV-LT-0013). The views expressed in this publication are those of the author(s) and not necessarily those of the National Institute for Health Research or the Department of Health and Social Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Solihull Research Ethics Committee, West Midlands gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
K.Nirantharan{at}bham.ac.uk, S.E.Hughes{at}bham.ac.uk, A.Subramanian{at}bham.ac.uk, O.L.Aiyegbusi{at}bham.ac.uk, elin{at}aparito.com, Puja.Myles{at}mhra.gov.uk, Tim.Williams{at}mhra.gov.uk, G.Turner.1{at}bham.ac.uk, J.S.Chandan.1{at}bham.ac.uk, C.McMullan{at}bham.ac.uk, J.M.LORD{at}bham.ac.uk, D.Wraith{at}bham.ac.uk, K.C.McGee{at}bham.ac.uk, A.Denniston{at}bham.ac.uk, T.Taverner{at}bham.ac.uk, L.Jackson.1{at}bham.ac.uk, E.Sapey{at}bham.ac.uk, G.Gkoutos{at}bham.ac.uk, K.M.Gokhale{at}bham.ac.uk, Edward.Leggett{at}mhra.gov.uk, Clare.Iles{at}mhra.gov.uk, chris.frost{at}aparito.com, gary.mcnamara{at}aparito.com, Amy.Bamford{at}uhb.nhs.uk, T.P.MARSHALL{at}bham.ac.uk, D.T.Zemedikun{at}bham.ac.uk, tlcstudy{at}bham.ac.uk, S.Marwaha{at}bham.ac.uk, N.Simms-Williams{at}bham.ac.uk, BrownKR{at}adf.bham.ac.uk, A.A.Walker{at}bham.ac.uk, K.Jones.2{at}bham.ac.uk, tlcstudy{at}bham.ac.uk, tlcstudy{at}bham.ac.uk, tlcstudy{at}bham.ac.uk, tlcstudy{at}bham.ac.uk, tlcstudy{at}bham.ac.uk, tlcstudy{at}bham.ac.uk, tlcstudy{at}bham.ac.uk, tlcstudy{at}bham.ac.uk, tlcstudy{at}bham.ac.uk, M.Calvert{at}bham.ac.uk
Author contributions SH and MC oversaw and contributed to the drafting of the entire manuscript with input from all co-authors. KN, AS, AD, TT, GG provided methodological and statistical expertise. JSC and OLA supported drafting the background and co-led the evidence review on post-viral syndromes. OLA was academic lead for patient and public involvement. KM, GP, JC, MSC, SK, YA, DES, LA, MB and HB provided expert patient input based on their lived experience of COVID and its long-term effects. SEH, MC and CM led the development of the Symptom Burden Questionnaire ™ for Long COVID. PM, TW, CI and EL provided expertise on CPRD Aurum data and the Interventional Research Service Platform. EHD and CF provided input on the use of Atom5™, ePROs and wearables. JL and DW provided subject and methodological expertise on the immunological analyses with input from KM. DZ and LJ drafted the sections on health econometrics. GT drafted the section on the over-the-counter medication survey. ES, AB, SM and TM provided clinical and public health expertise. GK supported data extraction from CPRD Aurum and is the creator of DExTER. KB and NSW supported revisions to the manuscript and referencing. AW and KJ provided administrative support for the project. AW assisted with usability testing and protocol development. All co-authors reviewed and approved the manuscript.
Funding statement This work is independent research jointly funded by the National Institute for Health Research (NIHR) and UK Research and Innovation (UKRI) (Therapies for Long COVID in non-hospitalised individuals: From symptoms, patient reported outcomes and immunology to targeted therapies (The TLC Study), COV-LT-0013). The views expressed in this publication are those of the author(s) and not necessarily those of the National Institute for Health Research or the Department of Health and Social Care.
Conflicts of interest MC is Director of the Birmingham Health Partners Centre for Regulatory Science and Innovation, Director of the Centre for the Centre for Patient Reported Outcomes Research and is a National Institute for Health Research (NIHR) Senior Investigator. MC receives funding from the National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, the NIHR Surgical Reconstruction and Microbiology Research Centre and NIHR ARC West Midlands at the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Health Data Research UK, Innovate UK (part of UK Research and Innovation), Macmillan Cancer Support, UCB Pharma, Janssen, GSK and Gilead. MC has received personal fees from Astellas, Aparito Ltd, CIS Oncology, Takeda, Merck, Daiichi Sankyo, Glaukos, GSK and the Patient-Centered Outcomes Research Institute (PCORI) outside the submitted work.
SEH is supported by the National Institute for Health Research (NIHR) Applied Research Centre (ARC), West Midlands at the University of Birmingham. SEH has received personal fees from Cochlear Ltd and Aparito Ltd outside the submitted work.
OLA receives funding from the NIHR Birmingham Biomedical Research Centre (BRC), NIHR Applied Research Centre (ARC), West Midlands at the University of Birmingham and University Hospitals Birmingham NHS Foundation, Innovate UK (part of UK Research and Innovation), Gilead Sciences Ltd, and Janssen pharmaceuticals, Inc. OLA declares personal fees from Gilead Sciences Ltd, GlaxoSmithKline (GSK) and Merck outside the submitted work.
CM receives funding from the National Institute for Health Research (NIHR) Surgical Reconstruction and Microbiology Research Centre, Innovate UK, and has received personal fees from Aparito Ltd outside the submitted work.
PM, TW, CI and EL are employees of CPRD, the data custodians for CPRD Aurum. CPRD is jointly sponsored by the UK government’s Medicines and Healthcare products Regulatory Agency and the National Institute for Health Research (NIHR). As a not-for-profit UK government body, CPRD seeks to recoup the cost of delivering its research services to academic, industry and government researchers through research user license fees.
JC is a lay member on the UK NICE COVID expert panel, a citizen partner to the COVID END Evidence Synthesis Network, PPI lead on the NIHR CICADA ME Study, patient representative at the EAN European Neurology Autonomic Nervous Systems Disorders Working Group, a member of the MRC/UKRI Advanced Pain Discovery Platform, and external board member of Plymouth Institute of Health. She also reports contracts with GSK and Medable.
All other co-authors have no relevant competing interests to declare.
Data statement Data for this project are not currently available for access outside the research team. Each of the datasets generated within the project may be shared when finalised but this will require an application to the data controllers. The data may then be released to a specific research team for a specific project dependent on the independent approvals being in place.
Data Availability
Data for this project are not currently available for access outside the research team. Each of the datasets generated within the project may be shared when finalised but this will require an application to the data controllers. The data may then be released to a specific research team for a specific project dependent on the independent approvals being in place.
